An EUA for Bamlanivimab - A Monoclonal Antibody for COVID-19

Date: November 30, 2020 Issue #:  1612Summary:  The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently diagnosed mild to moderate COVID-19 in patients who are ≥12 years old, weigh at least 40 kg, and are at high risk for progressing to severe disease and/or hospitalization (see Table 1).
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research